Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib-Reference-Cited by-同舟云学术

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

Published:2014-06-26 Issue:26 Volume:123 Page:4132-4135
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wodarz Dominik¹,Garg Naveen²,Komarova Natalia L.¹,Benjamini Ohad³,Keating Michael J.³,Wierda William G.³,Kantarjian Hagop³,James Danelle⁴,O’Brien Susan³,Burger Jan A.³

Affiliation:

1. Departments of Mathematics and Ecology and Evolutionary Biology, University of California, Irvine, CA;

2. Department of Diagnostic Radiology and

3. Department of Leukemia, MD Anderson Cancer Center, Houston, TX; and

4. Pharmacyclics Inc., Sunnyvale, CA

Abstract

Key Points During ibrutinib therapy, 1.7% of blood and 2.7% of tissue CLL cells die per day which is 3 and 5 times higher than without treatment. The fraction of CLL cells that redistribute into the blood during ibrutinib treatment represents 23.3% ± 17% of the tissue disease burden.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/26/4132/1377840/4132.pdf

Reference15 articles.

1. B cell receptor signaling in chronic lymphocytic leukemia.;Burger;Trends Immunol,2013

2. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).;Burger;Leuk Lymphoma,2013

3. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.;Advani;J Clin Oncol,2013

4. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

5. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hopf-bifurcation analysis of a stage-structured population model of cell differentiation;Physica D: Nonlinear Phenomena;2024-11

2. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling;PLOS Medicine;2024-07-22

3. Expression of CD226 on γδ T cells is lower in advanced chronic lymphocytic leukemia and correlates with IgA, IgG and LDH levels;Advances in Clinical and Experimental Medicine;2024-05-31

4. Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia;Cancers;2024-05-28

5. Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib;Frontiers in Oncology;2023-12-04